CDXC - Earnings call transcript Q3 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by and welcome to ChromaDex Corporation’s Third Quarter 2018 Earnings Conference Call. My name is Shannon, and I’ll be the conference operator today. [Operator Instructions] And as a reminder, this conference call is being recorded. This afternoon, ChromaDex issued a news release announcing the company’s financial results for the third quarter 2018.

If you have not reviewed this information, both are available within the Investor Relations section of ChromaDex’ website at www.chromadex.com. to Director conference Relations. of like Brianna over now Senior Gerber, FP&A would turn call the to I and Investor go ahead, Please Mrs. Gerber.

Brianna Gerber

of third Jaksch; Chief Executive Good future to the studies Rob the Fried; sales filings, call. Shannon. results, in cash and uncertainties Executive opportunities Officer, us operations. regulatory risk that quarter are future Chairman, future, results NIAGEN and Corporation’s Frank With future ChromaDex’ you, investor operating Chief as XXXX are new team, Thank today the Founder subject results plans and relating afternoon, ChromaDex prospects welcome results and expansion development ChromaDex’ business Officer, to of the the related add to statements Kevin trial ChromaDex’ statements, forward-looking and including future and timing of the future opportunities, Farr. in as Financial business trials, needs, well plans to TRU of research development such Today’s and financial anticipated investor markets, interest and performance clinical of include timing trial management to conference and to and call may clinical ChromaDex’

cause subject any future risks and to on Forward-looking this materially from as call of company’s actually to Many to activities have not or are ChromaDex’ that could assurance matters the activities statements results. with update actual the give conform forward-looking inherently on statements or and XX-Q, not with obligation to included these estimates statements’ annual These results company note the expectations. to forward-looking in Because are conference contained those this its call forward-looking intended in most the Form date any to the to results that Please relate represent and to the only date statements report conference factors no anticipated occurred, the differ XX-K results yet forward-looking after changes factors SEC. the assumes Form actual statements of statements. recently filed and ChromaDex’ risk uncertainties.

addition, company’s why call reconciliations presented financial of available such an this in company measures, financial GAAP to the release, the certain financial presents earnings are was company’s non-GAAP useful is appropriate measures the of investors. to the issued this and In measures, website, the and explanation information believes which on references non-GAAP afternoon

Finally, call our available Officer, via this website being the conference call recorded Rob pleasure The that, webcast. my over will is Chief With our it’s www.chromadex.com. section to Relations Executive turn webcast Fried. now the of at to be Investor at

Rob Fried

joining third Thank call. you, Brianna. for our Good investor quarter you XXXX afternoon, thank everyone and

aging metabolic and the Our levels. is NAD to is most by help mission reduced accumulation damage, the dietary in of from cell problem of cellular a world’s energy trusted with reduction resulting aging shows company. supplement Research that solve metabolic science-based associated being and the

Our only approach addresses the this effectively market the and on safely study today product to this problem, NIAGEN. solving scientific most that we’re suggest problem

health. researchers studies, And wide of presently being toxicology and millions NIAGEN conditions. patent a by range in examining institutions NAD. human is FDA’s also safe. of NIAGEN ChromaDex effective portfolio TRU brand and consumer recognized new safe Our and protections. a notified conducted and increasingly research the has And of dollars under importance dietary successfully been many of clinical and years Research NIAGEN of And and to TRU is is been twice NIAGEN in in patents generally that by NDI strategy health protected is as is program. important make an global this to XXX on raising regulatory successfully the approvals, strong has reviewed ingredient, notification FDA as our has invested NAD worldwide, shows studies levels over brand. NIAGEN

for over recent an call Before Frank? I Frank Jaksch developments will scientific results, in to Executive quarter update strategy and the on turn third Chairman, discussing research. our

Frank Jaksch

to aging. quarter Thank continues has while include of and range clinical collaborations And most neuroprotection approximately a today number cardiovascular you, total and human wide expand. obesity, health. areas cover the cognition, over finished NIAGEN prevalent health, of half human importance represent areas, of with of of these update, and The NAD the science collaborative health Collectively, research on these cardiovascular studies Since the two NR new on on we does last Rob. NIAGEN to signed validate trials.gov diabetes potential we’re that post this research. The research our insights the XX. it research XXX may human surrounding areas efficacy valuable total signed translate last only studies additional Not the grown for And with over research than benefit quarter. provides studies into focused collaborations. the a XX by of additional and more on NR,

scientific view We as a peer-review future publications increasing on consensus media also NR. benefits of attention could awareness this pipeline the for and which greater consumer NR, yield of

development an feasibility study, broader from the Relations weight the of accumulation Maryland area tolerance. In potential Type testing Russell was our as neuropathy. for larger into body NAD nerve With by the thermogenic study brown unregulated Biological mice altering U.S. In clinical damage. The this additional studies receiving on clinical since studies XXXX, failure. when the the as August heart of conditions. The mouse a glucose and or is of mice. studies on its the Life a list to disease University for XXXX, August In induces effects those Chemistry use link last the study time disease wellness to studied effects gene NR are plan published insight at in also in left the Rob since population. are that validation NAD trial are last or treating the completed fasting LVAD. effective we a another demonstrated increased that update. model clinical registered. elective of nearing of left eating section that to adipose for lean if heart have new determine pain relationship two to take and increased I’ll related neurodegenerative entitled heart NR impaired September human highlights subjects is and are will decreased full trials. that the on and that NR assist a disease Washington eventually heart SARMX an study spoke. and administration Fried. also fat our in the mutation clinical without diabetes pilot changing device with progressive for Dr. that one muscle the to treatment important ventricular the Currently, published the article October, NR is aging call associated The our healthy safety riboside a advanced neurodegenerative last in lean in provide if the literature may nicotinamide suggest The X I’d protein the teams therapy on the neuropathic just death website. thermogenic in analyzing a study of investigate function. found week who a neuropathy effects of with few XXXX, improved like Sciences NIAGEN and this response heart scientific body on The it cause that Dr. NIH is a benefits a to since of number mainly there product happened the and This the system leads modifying a diabetic trial are last NHLBI, from summary, Journal And and a response year other impact actively a published a important few via determine ventricular O’Brien even and The we This to tissue. of back patients measure the was an Rob? the metabolism planning pass research diabetic of diseases, data. upregulate warrants no Science healthy a these NR In same of change belief failure electrical hypothesis subgroup or after NAD James registered the human fat genetics in of function results and impact increase a publication the in showed on that, have will from of growing will study a is to that In can clinical the of NR NR help mitochondrial September game structure Investor the colleagues again. Here seeing SARMX is NR designed of in XXXX, will an highlight In in and to heart. a that important be immune human In University of NAD with in the trial molecular Parkinson’s dysfunction

Rob Fried

nine more grew NIAGEN and TRU third NIAGEN-related for NIAGEN-related TRU XXXX. compared In Thank net the for of accounting net XX%, net XXXX XX% sales the sales net to NIAGEN-related net up revenues. of for sales nine total first quarter revenues than overall revenue months quadrupled and the were for compared TRU quarter accounting months sales net with e-commerce quarter the of our year-to-date NIAGEN accounted with and were revenue by revenue second accounting NIAGEN XX% for of of XX% net NIAGEN-related you, third Frank. XX% first XX% TRU the sales results. the net XXXX, our quarter XX% of up nine sales up of increased revenues XX% Through third were our XX%. XX% the month revenues accounting XX% for net XXXX to TRU and revenue. NIAGEN total third to for for accounted the total of NIAGEN quarter and year-over-year of total total From

NIAGEN an renegotiated Watsons Our third achieved between are and June further assembling and our companies. general, started importance for healthcare months. healthcare team been progress it’s third extended the I milligram updating Lisa the capsule. new systems in quite should TRU importantly has as single NIAGEN healthcare platforms of coming in in in available most a TRU of providers, will and will We We XXX% exclusively an an sequentially XXX TRU as were which launched established network Chief the for who quarter NR significant grew the with help Officer, of an developing few capsules, two the accomplishments. They over PRO a that between practitioners partners which our sales is NIAGEN the of in States. dose partnership that bottles been the through the exciting on the of TRU Fullscript’s, PRO local global of natural quarter United comment highest revenues, Watsons sale the to opportunity important part and a important busy growth. very launch XX,XXX and in and available feature We channel agreement but shortly. excellent have Marketing NIAGEN. preparation grow the word Bratkovich, has market campaigns practitioner HCPs, see spread to in on new influencer including professionals

the NIAGEN contract big two opportunity has Watsons to Kong sales and earns next sport Additionally sports September on grow TRU years We for and TRU Globally, of great NSF extension interest XXXX. and International Macau potential. years. as is additional an community. Kong significantly program. are with There in distribution over dedicated Hong for in the an the Watsons certification to very XX, three our see in exclusive Hong an in this annual announced Macau realizing committed basis through from we NIAGEN certified a

spoke. explore led approvals will markets other economic In we international claim are soon NIAGEN conditions distribution We robust TRU still approvals launch and that Singapore. regulatory Watsons in marketing has in Turkey, we opportunities expectations worsened of us lower the last since the extend timing. to with Taiwan to on more and continue to have receive to hopeful health This

approved October all are in nicotinamide ingredient We claims addition, across riboside working been platforms diligent for to did not we have health an Canada, towards on of product XX, including In strong TRU NIAGEN approval regulatory NIAGEN. registration retailers. we sell approval has and although as TRU and brick-and-mortar received receive yet

very expansion University. to are the understanding market of China, stages of Jiangxi Province. approach Affiliated We up execution in geographic people of XXX another definitive a than partnership yet which more a actively large include to for of not is over step. Chromadex China yet between the exclusive research this are Nanchang for with China. that opportunities continue a in and other memorandum distributor territories. the partnership potentially market. an aging is a as agreement. And as time, memorandum strategy FDA take new our see the given million also approval the age This is determined We're in Last this represents. understanding First important Zealand. announced international opens in have as China early The for the taking we ChromaDex a but There quarter, of SuperFoods New will enormous announcement Hospital We're opportunity border province deliberate pursuing NIAGEN, well of signing but NIAGEN TRU cross XX here, we this could appointed creation a in important the of TRU Matakana strategic a in milestone

we is Oakland. has and September yet approval We NIAGEN been this made TRU have and Regulatory a opening international for in in markets XX critical consumer on in excellent. market have growth, approvals priority. regulatory launch coverage media this and challenging Initial response new

are with about Jiangxi Province. the world Canada, Watsons’ around New Zealand, the about this the important important brand the We product. know will partnership with excited People potential and and this

to Japan, Team she evaluation with the China growth appointed extensive sales Executive as our plan Hong help Asia-Pacific and Asia-Pacific well market Shop. our Manager continue us as Ms. relationship entry. for We bring Ms. We and overseeing international two of from of Kong, partnerships. us as She to functions our Regional The Adidas new Yan our health an Chu Managing strengthen responsible for Chu market Previously, ongoing hires Body Comvita, including our Director products Crocs, opportunities company, international experience. led served she drive as Management strategy, joins key where building be and Watsons’ market and and will General marketing in who Korea.

capabilities Chief Roberts, President. and Senior knowledge We scientific Officer strategy. familiar company. approvals the spent Advisory development, Matthew Board, outstanding the regulatory Scientific brings and also years He consumer quite in two announced and as Vice and with the already of business international a experience Matthew at is operations the ChromaDex appointment general Scientific of product also on wealth Having

Company. proud are our join We to him have

to We last excellent company. smooth I ensure five transition. dedication for announced he welcome the Troy but Rhonemus be While want years staying on Yan consultant when team. we the service and as Matthew resignation his to will his and a Executive ChromaDex to thank month, also Leadership a of to voluntary

contracts Dartmouth words few that against announced Let XX, Patent lawsuit vigorously, from the litigation. The legal misappropriation actions against a Health. me Elysium is secrets. has now College patent the we for filed breach trade separate what had On of of demonstrates a how developing. many This Elysium infringement years we September protect supply say about XXXX, and Chromadex company spent Litigation of and will course Chromadex’s the

the potential NIAGEN millions see world. very about on feel the summary, cases confident to around has expect return the investment. to impact litigation this people a the hundreds continue of to know facts In we that We of these of of important and lives and is

responsibility a to have We handle well. it

this we I poles and quarter. a enthusiastic the And the be third place our by the CFO, Farr. made I continue the we XX to ones now call I'm key progress few have Kevin quarter over encouraged great to past Kevin? added will future. and We in in pass about

Kevin Farr

Thank you, Rob.

look progress results our XXXX, of Let's continued financial third against key for financial at which the quarter objectives. our reflect

marketing in expenses, and when growth expansion, We exclude in especially legal costs. you discipline margin continue gross investments strong experience sales, to operating

XXXX. growth ended the third in of margins core quarter three TRU Gross third points NIAGEN down XX.X% up year-over-year. a Notably Breaking $X.X of better which year and to for compared for net earlier. for to business million, the NIAGEN which further, X% third continuing year. grew partially compared $X.X positive the reported will from XX.X% third roughly troubled months XX% We the quarter gross in the by compared represented NIAGEN TRU For businesses. quarter, doubled of XXX NIAGEN continuing XX% by experienced NIAGEN to of of with in third XXXX, the to sales offset to margins sales XX%, the last ingredients XX% September million up year's were basis and sales last quarter to third due NIAGEN to XX% revenues this XXXX, operations of our to ChromaDex million, declines XX% net $X.X by sales, operations were sales XX, in the profits in compared increased related TRU XXXX. TRU quarter of third third sales to the XXXX. We quarter increased XX% year, quarter the by compared revenues third related for of our XX% product compared up revenues of quarter quarter gross expected we anticipate impact consumer Sequentially, from was continue.

the in from incremental expenses the operating the as of administrative with quarter million quarter and Our of additional and support by growth third to Compared $X.X expenses continuing incurred $X.X sales expense quarter legal research increased advertising build out expenses development R&D compensation $X.X in in million additional made our compared Consistent up investments and non-cash $X.X our million. third and to XXXX, we in stock-based of of the to million by and to TRU business. million. and $XX $X.X to NIAGEN XXXX third marketing we cost expectations, invested were million marketing expenditures, of general million Incremental $X.X brand, operations.

compared to million and higher continuing million, stockholders of The per invest of the quarter The of to loss million, third XXXX. the expense quarter for the loss compared up $X.X decision in expenses a share the of to of a third was or the expense $X.XX $X.X net XXXX executives the common hiring $X stock-based offset of as attributable senior fees, as was by $X.X loss higher million ahead net the million growth result higher of operations million expenses from third including advertising of of third loss quarter net which higher of million legal per were XXXX. $X.X related quarter administrative strategic or to $X.X sales share for as gross $X.XX well loss compensation $X.X volume profits. and higher general legal to which compensation and and was equity-based of Excluding marketing, as by partially were in

million continuing negative was quarter million quarter in the solid a the million EBITDA from quarter. defines in prior Total to for ChromaDex in the of of $X.X a working third fair the quarter a of depreciation, XXXX, EBITDA, of a to was charge negatively this negative continuing to source a or the third cash were Adjusted is The outflows million cash the related of third adjusted basic diluted compared sheet in to for The quarter second of balance cost. and which used quarter cash in in for which million share by We a compensation, operations operating non-cash XXXX income $X.X from cash XXXX, $XXX,XXX $X.X interest, quarter non-GAAP $X.X loss with negative for XXXX, XXXX. of million net the of $X.X operations was income quarter of the million, adjusted primarily and of quarter third related $X.X was activities third a quarter XXXX. the third of second stock-based the stock $X.X charge a compared of of For the reporting to quarter our tax, measure million year. $X.XX versus capital, was non-cash XXXX EBITDA $X.X the of quarter. third third the versus which use adjusted outflows XXXX. to loss, a quarter gets $X.X In the EBITDA for the ended million $XX.X negative compensation as lower compared cash negative adjusted per million. amortization $X.XX third third in net with the cash impacted

to the cash for of continue positive working million capital expect we year. to a source $X year, full be of the full million $X For

tightly year. As losses we working and in capital our for manage balance net to the fourth moderate of continue the we to expect the quarter

The the the forward, business e-commerce by invest as expenses international and will driven certain company build be and continue company in growth TRU revenue will U.S. growth. new to expects NIAGEN TRU Looking in in our up markets. the Watsons' capabilities international business to brand well marketing NIAGEN to efficiently as support

our we'll protect in as cutting addition, In to the property. time, to the implemented At continue we've invest programs cost company spending. our reduce costs legal same necessary, across intellectual overall

much and had R&D to we've for NIAGEN develop spending, forward. that more R&D this to projects that additional support claims NIAGEN. commitments incremental we we primarily to example, products will XXXX. Investments marketing expect sales consumer moderate an appropriate pharmaceutical drive the we TRU related going targeted As Coming into year, in in expect

increases in advertising, of leveraging TRU sales as of gross take selling we're and marketing, our questions. legal management tools decisions company continued We a overhead support continue the into NIAGEN on effectively we expenses, to and net a the margins our In continued to TRU advertising, to to key will focus investments of for NIAGEN expenses be as summary, cost Operator, better the now returns. selling improving spending, as in solid growth our look efficiency possible. and profitability, drive and ready marketing, as drivers of the in sales managing percentage fixed improve get position

Operator

Thank Ladenburg you. with Cohen Instructions] Thalmann. Jeffrey [Operator comes Our first question from

is line Your open.

Destiny Buch

on This are How is actually Destiny you? Jeff. Hi, guys. for

Rob Fried

Great, thanks.

Kevin Farr

Hi Great. Destiny.

Destiny Buch

good. Good,

So I just questions. a have couple

quarter, management and out just what I'm of start Or so, are additions this pursuing current me areas? but if Let important you now? do that a fairly your know feel other very I is management like couple team people rounded team. with curious, your you added you

Rob Fried

now. We rounded feel is team the management fairly out

Destiny Buch

approval, do claim things FDA a would idea have or I not when that Okay, do pursuing also got you that you. approval, submit et like And submit or or currently? of you mentioned regulatory cetera anything you then you know any the providing get

Rob Fried

to CFDA, referring you Are regulatory approval? China

Destiny Buch

Yes, sorry. Hopefully, my connection CFDA, is bad not yes. too

Rob Fried

Province, now. the will authorities at have strong in in Obviously, is we given, the Government, pretty terms quite of any going have don't regulatory on transition that to but right the the all. Jiangxi be no Central There's as with No, China insights. when insights approval bit of we relationship a if

Destiny Buch

then talk got the this now were was can looking bit quarter What know, said year. you you additional a early at XXXX approval by about for you Turkey? some of an or it. And little the and are more I you Okay, there end later? mid-XXXX turbulence projecting

Rob Fried

because political Well, few economy the Watsons’ that and of Turkey, the us it's commercially in with hold even a idea issues issues off to on with Turkey Turkey probably for feels good a months. Turkey for

approvals, terms sells months. we think approval regulatory The so approvals receive product It's happen a it well also In receiving we the short, would the effectively of for approvals, that it's riboside. I nicotinamide the the claims take approval did may regulatory in product, as claims said, ingredient that shortly. claims We is some know not just market is Turkey. approval few will

Destiny Buch

now provide sense. more you Okay, also you term? which a on new expanding interested color little and territory. some And into would you one pursue Can that the makes you mentioned in near Thank you for that. are in

Rob Fried

Well, we're interested in Canada. certainly

We And But approval that are each a are regulatory encompass are And the process. has we its some Asia, obviously regulatory in would EU. quite regulatory pursuing other that country countries approval few throughout there pursuing. acts own countries.

Some are not. are quick. Most

Some are very slow.

a take employing where country strategy, countries time, world. painstaking process that one at but aggressive a around it's are very we a all the we So major

Destiny Buch

the thinking employ you brick-and-mortar, in like then And as but have a Canada, would now? U.S.? similar what an were also And you said then it. interests e-commerce seeing additionally, there you is you there of landscape I Are well? strategy as you right, know the All got

Rob Fried

are actually via we selling Canada into already Amazon. Yes,

are strategy and distributors not retailers is of a cross is in We also And deal are with we a with a is Canada, numerous examining. not that discussions potential an our border strategy them There we imminent. Canada television in but Canada soon for the have with will website. in or any

Destiny Buch

guys last I shipping Okay. to that and I cost you And then, forward? use continue and more you you those do sold. and quarter, one Did of this included know just that again handling have your costs. goods I quarter related going to believe, will

Kevin Farr

with revenue Yes, is we policy. election accounting quarter-after-quarter, applied be goods that's since regard of made And part election. our and that cost the it include consistently sold, recognition shipping will of to in to

Destiny Buch

Okay.

double Just All right. checking.

I now. think Thank for taking you that does it for the me for question.

Operator

Jeff Our Van next from question Sinderen B. with Riley. comes

is line Your open.

Jeff Van Sinderen

the on say the First, growth let in me quarter. congratulations

Rob Fried

Thank you, Jeff.

Jeff Van Sinderen

and those, have of early too it's providers Maybe Maybe on. the and you that share anything for healthcare how about one have working guess, thinking can trying now if to get you're months of just the certification. there's after few new a just some marketing plans you do some do better you you the I'm might sense thing but is looking go on talent more care we're I tell to there. how I'm you wondering events at marketing now. a us of any after of go with segment? for sports

Rob Fried

the market – But women audience is potential would say of the past, broader we have than the discovered for TRU NIAGEN pursued over NIAGEN that. a or Right. In age. singularly demographic that I has TRU quite actually the certain

and younger exploring been sports as the market have the market mentioned. healthcare you males, segments, we practitioner So other

indeed we that opportunity one NIAGEN already and this seems are we pursuing big and few are for beyond market throwing market, marketing when in very wide a the there NIAGEN what particular a notable been to experiments, taking and is some be bit TRU experimentation always athletes explores Now – quite has traditional that area new us have testing know are there the particular, our in But to costs are see aggressively. that net in of we there quite seen a involved in that we Sports, a very in demo. who interest have NIAGEN TRU TRU out our responds.

campaigns and the we In few and you on Lisa expect. that growth assembling As communicating type also a for a scalable also impressive Bratkovich Marketing of very been sufficiently developing Chief of June. been They've that new team ensure new hard new our has Lisa our mentioned, They marketers. systems began they to last creative Officer, we some in are working platforms have the for message. have months, been channels interesting

We encouraged are what coming not into are efforts not expect rushing in months bear these hopeful indeed will are very we by the campaigns market, new that but we into the and rushing we seeing market, the with and channels fruit. we are are

Jeff Van Sinderen

Okay, products, the then update the PRO so mentioned on you happening, if know NIAGEN is good. efforts the around status or us there? derivative I that works NIAGEN of are those think kind – PRO new can And in products, a maybe are you TRU of of plans some wondering I maybe and

Rob Fried

do we So delivery demand and that been is for NIAGEN there we those. a other of have developing aggressively methods see

we've deal hope we're as that of types and in a in the – be presently. test with we able two the shortly exploring, have also There announcing past, potential being and Juicery Coffee promising think capsules to forms that announce that of will has product other new fact, those we beyond we are market in selling available that those to delivery marketplace been in coming very hope and months. two with be the we other Bulletproof are we In that product we entities the a Pressed lot conjunction a announced a see companies, as

Jeff Van Sinderen

success. Okay, good. and continued taking for my questions Thanks

Rob Fried

you. Thank

Operator

next Our Selvaraju question from with Ram Wainwright. comes H.C.

is line open. Your

Julian Harrison

Julian is my This Thanks Selvaraju. for Ram taking question. Hi. on for

roll Watsons’ be of and which of relationship, could elaborate launched been the I pricing, it has more specifically just total via was on TRU the evolution the wondering, very of status in stores, First, helpful? out if you all countries NIAGEN would number

Rob Fried

Do to you do want that?

Frank Jaksch

XXX believe stores. it's I in

Kevin Farr

stores in XXX Kong in XXX It's stores and Hong about Singapore.

Rob Fried

other into particularly, We Taiwan expand Turkey. expect and then to countries,

will don't eagerly come a made regulatory hopeful We in are to in, Taiwan, given responses. First couple submissions. we responses. approval that months. difficult They've the know. control things. of these We've when addressed It's us comes coming some their the We've

important we and seem of today, to countries themselves but working are it. then in in equal Singapore TRU that Notwithstanding of process. interested Hong sale combined. stages Singapore, There's even we In countries and continue developing identify with can Singapore individual Kong interest stores Watsons which product stage, product. approval, products two can is can we As three to marketing. But in that aggressively we countries exploring. to some existing approximately Singapore, enough number there's be approved. our two in expressed feel have stores roll to so It's soon we them stores regulatory Watsons we the to in expanding and for health do are have approval, the are grow not there to Taiwan us into of one for for need ingredients Watsons seeking are claims distribute product that the out note have that The are also we the without their we strong hopeful them the additional we NIAGEN a something those that claims the that and the have extremely – has we other number is or countries. in in those country. not to are are market to market stage, And regulatory the we sufficient in the most in stage. that aggressively there the to get and successfully Watsons will claims that first

Unidentified Analyst

Okay. Got Thanks it. that. for

the those For – time? clinical this so, my guess about second generate question, over efficacy there at any data to you internal if concept you talk I able And years on of basis. an are proof of expect next are couple indications to

Rob Fried

on, is Frank defer you Frank. to I’ll but Yes,

Frank Jaksch

on, the sorry was Could you I’m repeat on I question again? mute.

Unidentified Analyst

Yes, sure.

data couple if the you expect this those can So, an that there internal concept talk of time? so, if are any on And at to on about basis. I of next clinical you was indications proof wondering over generate years

Frank Jaksch

up that’s most to successfully this of that a ribosides our further that studies timeline just don’t yet. another data for or that’s publishing confirm NAD. provide data But we ability so mean regarding further riboside to – and the released I coming going And on the ability line study be nicotinamide have and we’ve should top the to NAD raises raise nicotinamide own going Well, only far.

sort diseases. been associated cognition all trials.gov. of areas ones that with ones neurodegenerative we most and range The lately prominent call, of probably studies the posted but or stated a the are surrounding neurodegenerative that wide have health are the in cardiovascular really as on – the And are clinical there’s other

Rob Fried

about very excited are encouraged and a of we’re on There Yes. being studies which neuroprotection, series about. done

industry is be are also related I will where sleep most though conditions the muscle there’s Frank impact. studies that they the seems as think and there have on But to said, as It us a seems neurological-related aggressively. as indications. pursuing significant on also studies as cardiovascular well

Unidentified Analyst

When action. Elysium talk you the for That’s Health. great. And to able next question my court helpful. we about expect should Are Okay, that? the last regarding ongoing Thanks.

Rob Fried

trial There March. scheduled is for a

trial hope that case California that to the Elysium at the it For sticks begins we and that time. and

Unidentified Analyst

very Thanks great. much. Okay,

Operator

Thank you.

question comes Barry next Kitt Pinnacle with Our Fund. from

open. is line Your

Barry Kitt

heard players that that stopping symptoms down guys. Hi, what any came you traumatic already. there two that they was NIAGEN I’ve football asked and CTE, taking have it experiencing. experience were did and is that? My TRU And encephalopathy. Have had they are different, were who that chronic heard I it with one answered basically question. questions the I’ve were with ex-pro

Rob Fried

many teams us. neurological have with from had studies a health we’ve And But make have that other have effect. scientific contact but football Well, we to we could that CTE just published claim numerous we such issues. not players no people anecdotal communications and who

Barry Kitt

would studies go studies Are in that third-party ongoing, any that there direction?

Rob Fried

others, at on several. there School study specifically has There’s Yes, there’s you CTE to perhaps believe a And NIAGEN Clinic, also one on is I or Frank the and two their one one do Mayo in Medical but one proposed Alzheimer’s. to eager Antonio, us, San neurology of are on Harvard head know. there’s

Frank Jaksch

which neurological disorders, effect. brain all had of traumatic course numerous on been shown positive mice and injury a published very studies Alzheimer’s, Of there have that preclinical are

Kevin Farr

studies – that for it’ll And a potential of on the on And proxy hearing neuronal several neuronal it’s impact studies in to between axonal same have damage, hearing sort have area. shown those correlation there’s loss. loss impact also also there’s related damage and a

there’s So you one of them that measure. in can loss actually hearing

areas going loss So other TBI damage. or and I other hearing like or on to axonal you’re concussion see focus think areas neuronal associated with

Operator

And we Barry more one time question. to for have ask

Barry Kitt

was Thank it end the I you. appreciate Thank questions. you. guys. my That of

Rob Fried

Thank you, Barry.

Operator

turn we Brianna to the to Thank all for call is questions. the Gerber like remarks. for back you. That would time I closing have

Brianna Gerber

for and again. Eastern (XXX) available call Shannon, today. us all be call will replay time for and tonight. you of to PM number There joining a this is XXXXXXX. thank X:XX you, is replay XXX-XXXX Thanks beginning code The the Thank at the pass

Operator

Ladies for today’s and concludes Thank wonderful gentleman, your participation and have this a you day. conference.

ChromaDex (CDXC) 7 Nov 182018 Q3 Earnings call transcript